Editas Medicine to Participate in The JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor meetings at the JMP Securities Life Sciences Conference in New York on Wednesday, June 20, 2018.  Details of the panel are as follows:

Panel: Gene Editing – From Science to RealityDate: Wednesday, June 20, 2018Time: 8:00 a.m.Location: St. Regis Hotel, New York                          

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts

Media:Cristi Barnett   
(617) 401-0113[email protected]

Investors:Mark Mullikin(617) 401-9083[email protected]

You May Also Be Interested In

• Master the Moment: Global Broker FISG Appoints Football Legend Andrés Iniesta as Global Brand Experience Officer
• CRI Merges In Morrison & Smith, Expanding Alabama Footprint
• Hayati® Expands Its Commitment to Responsible Business Through Hayati® For Nature